1)三森経世.肥大性骨関節症の診断と治療.日内会誌 83:1943-1947, 1994
2)Friedreich N. Hyperostose des gasammten skelettes. Virchows Arch Pathol Anat 43:83-87, 1868
3)Touraine A, Solente G, Gole L. Un syndrome ostéodermopathique:la pachydermie plicaturée avec pachypériostose des extrémités. Presse Med 43:1820-1824, 1935
4)Vague J. La pachydermoperisotose. Ann Méd 51:152, 1950
5)Uppal S, Diggle CP, Carr IM, et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 40:789-793, 2008
6)Zhang Z, Xia W, He J, et al. Exome sequencing identifies SLCO2A1 mutations as a cause of primary hypertrophic osteoarthropathy. Am J Hum Genet 90:125-132, 2012
7)Umeno J, Hisamatsu T, Esaki M, et al. A hereditary enteropathy caused by mutations in the SLCO2A1 gene, encoding a prostaglandin transporter. PLoS Genet 11:e1005581, 2015
8)東根達也,三谷郁生,向山新,他.Pachydermoperiostosisの1例および本邦報告例130例の文献的考察.内科 64:948-952, 1989
9)肥厚性皮膚骨膜症における遺伝子診断と生化学検査を踏まえた新しい病型分類の提言と既存治療法の再評価に関する研究.平成22年度総括・分担研究報告書.
10)新関寛徳.肥厚性皮膚骨膜症(疾病番号165).Derma 257:63-72, 2017
11)Nakazawa S, Niizeki H, Matsuda M, et al. Involvement of prostaglandin E2 in the first Japanese case of pachydermoperiostosis with HPGD mutation and recalcitrant leg ulcer. J Dermatol Sci 78:153-155, 2015
12)Sasaki T, Niizeki H, Shimizu A, et al. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype-genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci 68:36-44, 2012
in a female patient with pachydermoperiostosis with an atypical phenotype. Br J Dermatol 170:1187-1189, 2014
of the SLCO2A1 gene. J Dermatol Sci 75:193-195, 2014
15)肥厚性皮膚骨膜症の診療内容の均てん化に基づく重症度判定の策定に関する調査研究班.肥厚性皮膚骨膜症(指定難病165).難病情報センターホームページ.http://www.nan byou.or.jp/entry/4604(2017/8/29)
16)Tanese K, Niizeki H, Seki A, et al. Pathological characterization of pachydermia in pachydermoperiostosis. J Dermatol 42:710-714, 2015
17)梅野淳嗣,江﨑幹宏,久松理一,他.非特異性多発性小腸潰瘍症(CEAS)の発症メカニズム.G.I.Res 24:328-335, 2016
18)Jojima H, Kinoshita K, Naito M. A case of pachydermoperiostosis treated by oral administration of a bisphosphonate and arthroscopic synovectomy. Mod Rheumatol 17:330-332, 2007
19)Li SS, He JW, Fu WZ, et al. Clinical, Biochemical and Genetic Features of 41 Han Chinese Families with Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib:Results from a 6 Months Prospective Clinical Intervention. J Bone Miner Res 2017[Epub ahead of print]